Breaking News

Opexa Makes Senior Management Changes

April 1, 2013

Names CFO, clinical ops execs

Opexa Therapeutics has made several key appointments to its management team. Karthik Radhakrishnan has been appointed chief financial officer, Kenny Frazier has been appointed vice president of clinical development and regulatory affairs, and Maryann Murray has been appointed as clinical development manager.
 
Mr. Radhakrishnan has more than 10 years of healthcare capital markets experience and most recently served as vice president at ING Investment Management in New York. Previously he was the senior analyst at Eagle Asset Management, responsible for large cap growth healthcare. 
 
Mr. Frazier joins the company from Lexicon Pharmaceuticals, where he served as senior director of clinical operations, responsible for overseeing project/program management, clinical research monitoring, drug supply management, data management, biostatistics, clinical trial associates, meeting planning and medical writing. Previously he was director of clinical operations at Tanox, Inc., responsible for the management and conduct of Phase I-IV trials across all therapeutic disciplines.
 
Ms. Murray previously was a research coordinator at The University of Texas Health Science Center. She has many years of experience as a clinical research manager at several neurology centers, including the site that conducted Opexa’s Phase I studies of Tcelna. 
 
“We are very pleased to be strengthening the Opexa team with such highly qualified individuals,” said Neil K. Warma, president and chief executive officer of Opexa. “Karthik’s financial expertise and understanding of the investment environment will be a tremendous asset to help us realize the full value of our clinical programs. He has a wealth of experience and a strong network from which to draw, having spent several years in the center of New York City’s investment hub. He and his family will be relocating to The Woodlands area. We would also like to thank David for his recent oversight of the finance function, and we look forward to his continued contribution on our board.”

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016